Agios
Manufacturing · Massachusetts, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
88 Sidney St, Cambridge, Massachusetts, ...Phone Number
(617) 649-8600Website
www.agios.comRevenue
$66 MillionStock Symbol
AGIOIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
6
1
2
1
2
About Agios
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Explore more
Agios Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Agios your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Agios is spiking on competitors!
Click to see if Agios had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Agios
Funding: Get notified immidiatlly once Agios has new funding data
Earning: See what the market has to say on Agios recently announced quarterly report
Check if Agios has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Agios launches new products
Agios, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Agios
Compare insights from companies similar to Agios, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$675.1M
1K - 5K
Private
$225M
2009
KD
Kristen DravesDirector, Head of Business Strategy and Operations. Chief of Staff
Company Profile Activity
Activity Insights
Agios is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Agios is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Agios.
Agios financials insights
Gather financial insights about Agios, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$106M
Agios Tech Stack
A closer look at the technologies used by Agios
See more technologies
Most Recent Scoops
Open Position
Person-Based
Pharmaceuticals
Hiring Plans
Agios has more open roles in Information Technology than it has had at any time in the past 12 months. Technologies mentioned include: Oracle Fusion.
Hiring Plans
Hiring Plans
Agios is hiring in Human Resources for the first time in 12 months.
Hiring Plans
Person-Based
Pharmaceuticals
Agios News & Media
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Agios showcases RISE UP Phase 3 results at EHA 2026 Plenary Session reinforcing strong anti-hemolytic profile of mitapivat in sickle cell diseaseAgios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Agios announces an agreement with Oscotec to license the exclusive global rights to cevidoplenib, a novel, next generation, oral SYK inhibitorAgios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Agios provides update on Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromesAgios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
PYRUKYND (mitapivat) approved in the European Union for adults with thalassemia
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Agios
Sign Up For FreeTo access detailed company insights
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator fo... Read More
